A Phase 2, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of AGN-190584 in Subjects With Pseudophakic Presbyopia
Latest Information Update: 01 Jul 2022
At a glance
- Drugs Pilocarpine (Primary)
- Indications Presbyopia
- Focus Adverse reactions
- Acronyms ARIES
- Sponsors Allergan
Most Recent Events
- 24 Jun 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 10 Jun 2022 Planned initiation date changed from 21 Jun 2022 to 9 Jun 2022.
- 01 Jun 2022 New trial record